BOULDER, Colo., Sept. 14 /PRNewswire/ -- Source MDx today announced the launch of a set of new oncology biomarker services for targeted cancer therapy development, Source MDx OncoProfiling(SM), which includes the capture and enrichment of live Circulating Tumor Cells (CTCs) and Circulating Endothelial Cells (CECs) for off-line high-precision gene expression analysis with over 850 validated and patented targeted gene assays. These new services will expand upon current oncology offerings of detection and enumeration of CTCs and CECs. The Source MDx OncoProfiling gene expression service provides the molecular response of specific genes of interest from a patient’s whole blood, tumor tissue or circulating rare cell samples. Source MDx’s unique cell biology capabilities will provide pharmaceutical and biotech companies with a more targeted approach to development of cancer therapies, and allow a better understanding of the molecular differences and response to therapy of the primary tumor versus the metastasized cancer.
